TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir shares 8 Presentations highlighting company's transformational technology innovations at TCT 2023.
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
The DESyne BDS Plus RCT includes 202 patients across 14 sites in Europe, New Zealand and Brazil.